Program/Poster: Hall A – PO417
AAO 2010 Annual Meeting, Chicago USA, 2-6 May 2010
Presentation: Monday, Oct 18 2010 11:00AM-12:30PM
Authors
Ted Maddess1, PhD; Christian J Lueck1,2, MD, FRCP;
Cristian Voicu1,2, MD, PhD; and Andrew Charles James1, PhD.
1ARC Centre of Excellence in Vision Science, Australian National University, Canberra, Australia
2Department of Neurology, The Canberra Hospital, Canberra, Australia.
Purpose
To examine the diagnostic power of the TrueField Analyzer (TFA) in multiple sclerosis (MS).
Methods
Thirty-five normal (47.9 ± 16.8 years, 22 women) and 85 MS subjects (49.8 ± 11.3 years, 62 women) were enrolled; including 2 primary and 11 secondary progressives (PS), the remainder relapsing remitting (RR). EDSS scores for RR patients were 3.53 ± 1.04 (mean ± SD), and 5.9 ± 1.43 for PS. The TFA stimuli tested 44 regions/eye within the central 60 degrees.
Results
%AUC for the 144 RR eyes was 75.0 ± 3.31 (mean ± SE) and for the 26 PS eyes it was 94.8 ± 3.55. For RR patients that had or had not experienced ON, %AUC was 75.7 ± 4.48 and 75.4 ± 3.84, respectively.
Conclusion
ON had no significant effect, and PS patients had %AUC consistent with EDSS scores, suggesting that the results were more dependent on “secondary” degeneration than inflammation history.


